# Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults

> **NCT04973449** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2843 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** AZD1222
- **BIOLOGICAL:** AZD2816

## Key facts

- **NCT ID:** NCT04973449
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-27
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-08-02
- **Target enrollment:** 2843 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04973449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04973449, "Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04973449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*